Afucosylation boosts ADCC activity. Biointron outlines this glycoengineering strategy that enhances antibody potency and clinical outcomes.
Antibody glycosylation affects stability and function. Biointron explores how sugar modifications influence efficacy, safety, and therapeutic performance.
Afucosylated antibodies enhance ADCC for stronger therapies. Biointron highlights their mechanism and clinical applications improving efficacy across treatments.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
